



## Paradigm Biopharmaceuticals Company Profile

### Overview

Paradigm Biopharmaceuticals listed on the ASX in August 2015, and is focused on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic, heart, respiratory and viral applications. PPS is an FDA approved drug, developed in Germany in 1949, and has established anti-inflammatory and anti-thrombotic properties. It has been in used for over 60 years, and as such its safety profile has been firmly established. The Company addresses conditions that start with and are sustained by inflammation. Lead clinical indications involve:

1. bone marrow edema (BME) associated with osteoarthritis (OA) or acute injuries (ACL) – Phase 2a open label clinical trial with BME in ACL – Results due Sept/Oct 2017. OA open label SAS data due September 2017.
2. alpha-viruses (Ross River and CHIKV) – Phase 2a placebo controlled clinical trial results due Q1CY2018.
3. allergic rhinitis (hay fever), COPD and allergic asthma – Phase 2b results reported June 2017 – missed primary end point.
4. heart failure (cardiac remodelling) – pre-clinical.
5. Paradigm also holds IL-1RA Peptide, which is potentially a safe and stable treatment for multiple auto-immune related indications – Safety and efficacy confirmed in Phase 1/2 Clinical Trial (n:26) in the management of cancer-related cachexia (subcutaneous).

### Speaker Profile

#### Paul Rennie, Managing Director



Paul Rennie, Managing Director (BSc, MBM, Grad Dip Commercial Law, MSTC), has extensive sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialisation of Recaldent® a novel biopharmaceutical arising from research at the dental school, University of Melbourne.

*continued...*



Paul took this R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul founded Paradigm in early 2015.

For further information, please visit: [paradigmbiopharma.com](http://paradigmbiopharma.com)